Background: The scheduled update to the German S3 guidelines on fibromyalgia syndrome (FMS) by the Association of the Scientific Medical Societies ("Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften", AWMF; registration number 041/004) was planned starting in March 2011.
Materials And Methods: The development of the guidelines was coordinated by the German Interdisciplinary Association for Pain Therapy ("Deutsche Interdisziplinären Vereinigung für Schmerztherapie", DIVS), 9 scientific medical societies and 2 patient self-help organizations. Eight working groups with a total of 50 members were evenly balanced in terms of gender, medical field, potential conflicts of interest and hierarchical position in the medical and scientific fields. Literature searches were performed using the Medline, PsycInfo, Scopus and Cochrane Library databases (until December 2010). The grading of the strength of the evidence followed the scheme of the Oxford Centre for Evidence-Based Medicine. The recommendations were based on level of evidence, efficacy (meta-analysis of the outcomes pain, sleep, fatigue and health-related quality of life), acceptability (total dropout rate), risks (adverse events) and applicability of treatment modalities in the German health care system. The formulation and grading of recommendations was accomplished using a multi-step, formal consensus process. The guidelines were reviewed by the boards of the participating scientific medical societies.
Results And Conclusion: Meditative movement therapies (qi gong, tai chi, yoga) are strongly recommended. Acupuncture can be considered. Mindfulness-based stress reduction as monotherapy and dance therapy as monotherapy are not recommended. Homeopathy is not recommended. In a minority vote, homeopathy was rated as "can be considered". Nutritional supplements and reiki are not recommended. The English full-text version of this article is available at SpringerLink (under "Supplemental").
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00482-012-1178-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification and Management of Medical Comorbidities in Patients With HR+/HER2- Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: Literature Review and Recommendations From Experts in Spain Opinion.
Clin Breast Cancer
December 2024
Navarra University Hospital, Pamplona, Navarra, Spain. Electronic address:
Approximately one-third of patients with breast cancer have comorbidities at the time of their diagnosis. Recommendations for managing metastatic breast cancer are usually based on the results of clinical trials, which often limit patients with comorbidities. However, comorbidities greatly influence the quality of life, patient survival rate and treatment choice, particularly in older patients.
View Article and Find Full Text PDFPrevalence of dry eye in Brazil: Home survey reveals differences in urban and rural regions.
Clinics (Sao Paulo)
January 2025
Department of Ophthalmology, Otorhinolaryngology, and Head & Neck Surgery, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil. Electronic address:
Purpose: A random home visit search investigated the prevalence and predictors of Dry Eye (DE) symptoms in Brazil.
Methods: Through home visits to 420 urban and 180 rural residences in the countryside of Southeast Brazil, the Dry Eye Disease Short Questionnaire (DEDSQ) was applied to volunteers 40 years and older. The predictive value of the DEDSQ and the risk factors were investigated.
Entangled Illnesses: Embodied Experiences of Managing Multimorbidity.
Sociol Health Illn
February 2025
Tampere Centre for Science, Technology and Innovation Studies, Faculty of Social Sciences, Tampere University, Tampere, Finland.
Multimorbidity, meaning multiple long-term conditions impacting a person's health, has become a rising societal and public health issue. The article contributes to the sociological study of chronic illness and multimorbidity by analysing how the blurriness of illnesses and entanglement of symptoms in multimorbidity is experienced and negotiated by people with coexisting chronic conditions. Drawing on qualitative interviews with people who live with endometriosis, fibromyalgia or hormonal migraine in Finland, we show how people with multiple chronic conditions distinguish between evolving symptoms based on past embodied experiences to make decisions about how to best manage their health.
View Article and Find Full Text PDFRisk factors affecting the therapeutic effect of onabotulinum toxin a on chronic migraine.
Pain Manag
January 2025
Neurology Department, Centro Hospitalar Universitário de São João, Porto, Portugal.
Background: OnabotulinumtoxinA demonstrates effectiveness in chronic migraine prevention but is hindered by variable patient responses. This study aims to identify modifiable and non-modifiable risk factors influencing the response to onabotulinumtoxinA.
Methods: We conducted a retrospective cohort study at a tertiary hospital involving chronic migraine patients treated with onabotulinumtoxinA.
Rome Foundation Working Team Report on overlap in disorders of gut-brain interaction.
Nat Rev Gastroenterol Hepatol
January 2025
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
In patients with disorders of gut-brain interaction (DGBI), overlapping non-gastrointestinal conditions such as fibromyalgia, headaches, gynaecological and urological conditions, sleep disturbances and fatigue are common, as is overlap among DGBI in different regions of the gastrointestinal tract. These overlaps strongly influence patient management and outcome. Shared pathophysiology could explain this scenario, but details are not fully understood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!